Trials / Sponsors / OncoC4, Inc.
OncoC4, Inc.
Industry · 9 registered clinical trials — 4 currently recruiting.
| Status | Trial | Phase | Started |
|---|---|---|---|
| Not Yet Recruiting | Safety, Pharmacokinetics (PK), and Efficacy of ONC-783 in Advanced Solid Tumors Advanced Solid Tumor | Phase 1 | 2026-06-01 |
| Recruiting | Safety, Pharmacokinetics, and Efficacy of AI-081, a Bispecific Antibody for PD-1 And VEGF in Advanced Solid Tu Advanced Solid Tumor | Phase 1 / Phase 2 | 2025-03-26 |
| Recruiting | Safety, Pharmacokinetics (PK), and Efficacy of ONC 841 in Advanced Solid Tumors Advanced Solid Tumor | Phase 1 | 2024-08-23 |
| Withdrawn | Safety, Tolerability, Immunogenicity and Pharmacokinetics of ONC-841 Advanced Solid Tumor | Phase 1 | 2024-06-01 |
| Active Not Recruiting | ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC Metastatic Castration-resistant Prostate Cancer | Phase 1 / Phase 2 | 2023-12-11 |
| Active Not Recruiting | Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors Melanoma, Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma | Phase 1 | 2023-07-11 |
| Recruiting | ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors Non Small Cell Lung Cancer | Phase 3 | 2023-06-28 |
| Active Not Recruiting | ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer Ovarian Cancer, High Grade Serous Adenocarcinoma of Ovary, Primary Peritoneal Carcinoma | Phase 2 | 2022-12-22 |
| Active Not Recruiting | Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and Non Small Cell Lung Cancer, Advanced Solid Tumor, Metastatic Melanoma | Phase 1 / Phase 2 | 2020-09-16 |